SCHEMBL20570809

SCHEMBL20570809

COC(=O)c1ccc(Nc2nc3nonc3nc2Nc2ccccc2F)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
TP53 P04637 3/20 0.60
CDKN1A P38936 1/20 0.60
KDM4E B2RXH2 4/20 0.53
HTT P42858 2/20 0.53
NPC1 O15118 1/20 0.53
NFKB1 P19838 1/20 0.53
RAB9A P51151 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
LMNA P02545 1/20 0.47
TSHR P16473 1/20 0.47
AURKA O14965 3/20 0.47
PDE5A O76074 1/20 0.46
ABCC1 P33527 1/20 0.46
ABCG2 Q9UNQ0 1/20 0.46
SIRT2 Q8IXJ6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20569976 0.87 TP53 (0.60) MAPTSMN1; SMN2TP53CDKN1AKDM4E
SCHEMBL6412922 0.84 MAPT (0.46) MAPTSMN1; SMN2TP53CDKN1AKDM4E
SCHEMBL6412928 0.84 MAPT (0.46) MAPTSMN1; SMN2TP53CDKN1AKDM4E
SCHEMBL20569977 0.83 TUBB4A (0.49) MAPTSMN1; SMN2TP53CDKN1AKDM4E
SCHEMBL6412931 0.82 KMT2A (0.42) MAPTSMN1; SMN2TP53CDKN1AKDM4E
SCHEMBL22542867 0.82 GAA (0.57) MAPTSMN1; SMN2TP53CDKN1AHTT
SCHEMBL30754768 0.82 GAA (0.57) MAPTSMN1; SMN2TP53CDKN1AHTT
SCHEMBL20570336 0.81 SMN1; SMN2 (0.57) MAPTSMN1; SMN2TP53CDKN1AHTT
SCHEMBL31741920 0.81 SMN1; SMN2 (0.50) MAPTSMN1; SMN2TP53CDKN1AHTT
SCHEMBL22543309 0.81 SMN1; SMN2 (0.50) MAPTSMN1; SMN2TP53CDKN1AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11896591-B2 Compositions and methods for preparing and using mitochondrial uncouplers UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2024-02-13 US claimed
EP-3630115-B1 COMPOSITIONS AND METHODS FOR PREPARING AND USING MITOCHONDRIAL UNCOUPLERS UNIV VIRGINIA PATENT FOUNDATION (US) 2025-12-10 EP disclosed
US-11896591-B2 Compositions and methods for preparing and using mitochondrial uncouplers UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2024-02-13 US disclosed
US-20200323846-A1 COMPOSITIONS AND METHODS FOR PREPARING AND USING MITOCHONDRIAL UNCOUPLERS UNIVERSITY OF VIRGINA PATENT FOUNDATION (US) 2020-10-15 US disclosed
US-20200323846-A1 COMPOSITIONS AND METHODS FOR PREPARING AND USING MITOCHONDRIAL UNCOUPLERS UNIVERSITY OF VIRGINA PATENT FOUNDATION (US) 2020-10-15 US disclosed
EP-3630115-A1 COMPOSITIONS AND METHODS FOR PREPARING AND USING MITOCHONDRIAL UNCOUPLERS University Of Virginia Patent Foundation (US) 2020-04-08 EP disclosed
WO-2018217757-A1 COMPOSITIONS AND METHODS FOR PREPARING AND USING MITOCHONDRIAL UNCOUPLERS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2018-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11896591-B2 Compositions and methods for preparing and using mitochondrial uncouplers ACAD9, GPR119, NDUFAF1 MAPT 3834/4885SMN1; SMN2 334/4885TP53 3537/4885
US-20200323846-A1 COMPOSITIONS AND METHODS FOR PREPARING AND USING MITOCHONDRIAL UNCOUPLERS ACAD9, GPR119, NDUFAF1 MAPT 3834/4885SMN1; SMN2 334/4885TP53 3537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.